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We investigated effects of pharmacological triggering of exchange protein directly activated by cyclic-
3′,5′-adenosine monophosphate (Epac) on Nav1.4 currents from intact murine (C67BL6) skeletal 
muscle fibres for the first time. This employed a loose patch clamp technique which examined ionic 
currents in response to superimposed 10-ms V1 steps to varying degrees of depolarisation, followed 
by V2 steps to a fixed, +100 mV depolarisation relative to resting membrane potential following 
40 mV hyperpolarising prepulses of 50 ms duration. The activation and inactivation properties of the 
resulting Na+ membrane current densities revealed reduced maximum currents and steepnesses in 
their voltage dependences after addition of the Epac activator 8-(4-chlorophenylthio)adenosine-
3′,5′-cyclic monophosphate (1 µM) to the bathing Krebs-Henseleit solutions. Contrastingly, voltages 
at half-maximal current and timecourses of currents obtained in response to the V1 depolarising steps 
were unchanged. These effects were abolished by further addition of the RyR-inhibitor dantrolene 
(10 µM). In contrast, challenge by dantrolene alone left both currents and their parameters intact. these 
effects of Epac activation in inhibiting skeletal muscle, Nav1.4, currents, complement similar effects 
previously reported in the homologous Nav1.5 in murine cardiomyocytes. They are discussed in terms 
of a hypothesis implicating epac actions in increasing RyR-mediated sR Ca2+ release resulting in a Ca2+-
mediated inhibition of Nav1.4. The latter effect may form the basis for Ca2+-dependent Na+ channel 
dysregulation in SCN4A channelopathies associated with cold- and K+-aggravated myotonias.
Intracellular cellular 3′-5′-cyclic adenosine monophosphate (cAMP) is known to activate protein kinase A 
(PKA)-mediated phosphorylation of a wide range of regulatory cellular Ca2+ signalling molecules. However, 
recent intense interest has concerned alternative or co-existent PKA-independent activation mechanisms par-
ticularly involving exchange proteins directly activated by cAMP (Epac) in distinct critical cell physiological 
processes. Yet few studies report on Epac-mediated regulation of excitable membrane, as opposed to metabolic, 
signalling1,2, in particular involving ryanodine receptor (RyR) function or its downstream effects on Na+ channel 
(Nav)-mediated signalling. Those studies available were restricted to cardiac myocytes. Thus, in intact in situ  
murine ventricular and atrial myocytes, challenge by the cAMP analog 8-(4-chlorophenylthio)-2′-O-
methyladenosine 3′,5′-cyclic monophosphate (8-CPT) at concentrations specifically acting on Epac as opposed to 
PKA3 inhibited voltage-dependent Na+ currents under loose patch clamp recording conditions under which their 
intracellular Ca2+ homeostasis conditions were thereby preserved4. This accompanied pro-arrhythmic reductions 
in action potential conduction velocities in intact perfused hearts5. Both actions were reversed by the ryanodine 
receptor (RyR) blocker dantrolene which by itself contrastingly did not alter Na+ currents4.
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These findings were consistent with an action of Epac activation upon Nav1.5 through an increased 
RyR-mediated sarcoplasmic reticular (SR) Ca2+ release that would in turn modify Nav1.5 function. In murine 
cardiomyocytes, Epac is thought to cause a downstream RyR phosphorylation stimulating SR Ca2+ release thereby 
modifying Ca2+ homeostasis. Thus, the Epac activating agent, 8-CPT, elicits occurrences of spontaneous cytosolic 
Ca2+ ([Ca2+]i) transients. It also increases the amplitudes of evoked [Ca2+]i transients following action potential 
excitation. Finally, it results in an appearance of spontaneous propagated cytosolic Ca2+ waves in rat and mouse 
cardiomyocytes6. These findings were accompanied by pro-arrhythmic extrasystolic electrophysiological events 
in intact perfused hearts7–10. Both effects persisted in the presence of the PKA inhibitor H-8911. However, they 
were abolished by genetic ablation of Epac2, β1-adrenoreceptors or Ca2+/calmodulin-dependent protein kinase II 
(CaMKII)-δ, as well as by RyR2-S2814 phosphorylation12. The resulting altered [Ca2+]i in turn could then poten-
tially modulate voltage-gated Na+ channels (Nav) that generate propagated action potentials. The intracellular 
C-terminus domains of cardiac Nav1.5 possess EF hand-like motifs to which Ca2+ can bind directly. Nav1.5 also 
possesses an IQ-like domain to which Ca2+ can bind indirectly via calmodulin (CaM) as well as phosphorylation 
sites for CaMKII13. Different reports have variously implicated all three of these sites in the modified or inhibited 
Nav1.5 function14–17 observed when intracellular Ca2+ was varied in patch-clamped cardiomyocytes18.
Skeletal myocytes represent a cell type distinct from cardiac myocytes. They express differing skeletal mus-
cle RyR1, rather than cardiac RyR2, isoforms. These are activated by direct charge coupling as opposed to 
Ca2+-induced Ca2+ release, by differing surface membrane Cav1.1 as opposed to Cav1.2 L-type Ca2+ channel iso-
forms, not involving activation of membrane Ca2+ current19. These events are initiated by depolarisation driven 
by Nav1.4 rather than Nav1.5 channel opening. Furthermore, abnormal skeletal muscle Nav1.4 and cardiac 
muscle Nav1.5 function cause distinct clinical consequences. Genetic abnormalities affecting Nav1.5 potentially 
cause clinical cardiac pro-arrhythmic effects. Nav1.4 dysfunction is contrastingly implicated in hyperkalaemic 
and hypokalaemic periodic paralysis20–22, paramyotonia congenita21, cold- and K+-aggravated myotonia23, and 
sudden infant death syndrome24. Cold- and K+-aggravated myotonias particularly are associated with compro-
mised Ca2+-mediated regulation of Nav1.425.
However, in common with cardiomyocytes, skeletal myocytes possess G-protein coupled β-adrenergic recep-
tors which generate cAMPi on activation26. Furthermore, homologies between Nav1.4 and Nav1.5 are compat-
ible with similarities in functional properties13. In preliminary reports, Nav1.4 function was inhibited by Ca2+ 
entry through neighbouring Ca2+ channels, photorelease of caged Ca2+ in transfected HEK293 cells and skeletal 
muscle cell lines25, and following release of mitochondrial Ca2+ in murine skeletal muscle fibres27. CaM overex-
pression similarly negatively shifted steady-state voltage-dependences of Nav1.4 inactivation. This was rescued 
by expressing mutant CaM with impaired Ca2+ binding28,29. However, this evidence largely derives from cultured 
or heterologous cell lines studied by whole-cell patch-clamp methods that themselves perturb intracellular Ca2+ 
homeostasis. Furthermore, other reports demonstrated inhibitory effects of Ca2+ and CaM on Nav1.4 even under 
conditions when they did not inhibit cardiac Nav1.528. Finally, previous explorations of Epac actions in skeletal 
myocytes concerned actions of Epac1 in inhibiting proteolysis, inducing mitochondrial biogenesis30 and regulat-
ing AMP-activated protein kinase31. They did not study electrophysiological effects.
The present experiments explore downstream effects of Epac activation on skeletal Nav1.4 function, charac-
terised by Na+ current activation and inactivation properties, through its action on RyR1-mediated release of 
intracellularly stored Ca2+ for the first time. They studied mammalian, murine, muscle, thought to share many 
genetic and physiological properties with in situ human skeletal muscle32. Transcriptome analyses has demon-
strated close similarities between murine soleus and human skeletal muscle33. Mouse models are amenable to 
further detailed studies of recently available genetically modified murine Epac1−/− and Epac2−/− variants34. The 
present experiments employed the Epac activator 8-CPT and controls using the RyR inhibitor dantrolene compa-
rable with manoeuvres previously used to explore parallel regulatory features of Nav1.5. They similarly used loose 
patch clamp recordings and its related pulse protocols. Such experimental configurations similarly minimised 
intracellular perturbations particularly those involving [Ca2+]i homeostasis associated with conventional patch 
clamp methods4.
Results
Currents obtained in the combined pulse protocol. The loose patch clamp technique alters trans-
membrane voltage by changing the voltage on the extracellular rather than the intracellular side of the intact 
membrane under study (Fig. 1a,b). Accordingly, positive voltage changes in the intrapipette potential result in 
membrane hyperpolarisation relative to the resting membrane potential (RMP) and negative changes in the 
intrapipette potential result in membrane depolarisation relative to the RMP. For clarity the signs of the voltage 
steps applied to the pipette have been inverted when describing the pulse protocols so that they represent the 
changes in the conventionally-expressed membrane potential relative to the RMP. Accordingly, in Fig. 1c, depo-
larising voltage steps relative to the RMP correspond to negative changes, and hyperpolarising voltage steps to 
positive changes in pipette potential. The patched membrane was initially held at the RMP for 5 ms following 
the onset of recording. A pre-pulse hyperpolarising V0 voltage step from the RMP to a membrane potential of 
(RMP-40) mV of duration 50 ms was applied to remove any residual Na+ channel inactivation that might exist 
at the RMP. It would maximise and standardise the proportion of Na+ channels in the resting state relative to the 
inactivated state prior to imposition of the remaining V1 and V2 voltage steps. Use of the double pulse protocol 
allowed an analysis of the voltage-dependences of both Na+ current activation and inactivation within the same 
protocol (Fig. 1c). Thus, depolarising V1 voltage steps of 10 ms duration were then made to membrane poten-
tials between (RMP-40) mV to (RMP + 120) mV through successive sweeps in 5 mV increments. The currents 
obtained in response to these were used to investigate the voltage-dependence of Na+ current activation. In each 
sweep, this was then followed by superimposing a further V2 voltage step to a constant strongly depolarised mem-
brane potential of (RMP + 100) mV. This would activate the remaining Na+ channels which had not entered the 
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inactivated state by the end of the prior depolarising V1 step. Currents from this second step accordingly allowed 
characterisation of the degree of Na+ current inactivation induced by the preceding varying V1 steps, and thus the 
voltage-dependence of Na+ current inactivation.
Figure 1d illustrates a typical pipette current trace recorded during a single sweep in the protocol follow-
ing correction for residual leakage by a P/4 protocol in which the V1 step was made to a membrane potential 
of (RMP + 40) mV. Inward currents are represented as downward, negative, deflections and outward currents 
as upward, positive, deflections. Records typically began with a small upward deflection in response to the V0 
pre-pulse to a membrane potential of (RMP-40) mV. The initial V1 test voltage steps yielded early inward current 
transients, I1, whose amplitudes enabled quantification of activation. The subsequent V2 voltage step similarly 
elicited inward currents, I2, whose amplitude would be expected to vary with the inactivation expected to take 
place with the preceding pulse V1. The amplitudes of I1 and I2 were measured in relationship to the current 
recorded just before the V1 and V2 voltage steps respectively. The magnitude of I1 would represent the degree of 
Na+ current activation in response to V1 while changes in I2 would provide measures of the degree of Na+ current 
inactivation produced by the preceding V1 voltage step. The Na+ current amplitudes, I1 and I2, in response to the 
respective V1 and V2 voltage steps thus permitted quantification of the voltage-dependences of Na+ current acti-
vation and inactivation respectively.
The protocols were organised to monitor and correct for any monotonic drifts in current. We thus first applied 
a sequence of sweeps ordered from the smallest to the largest V1 voltage steps. We then repeated this procedure in 
the reverse order from the largest to the smallest V1 voltage steps. The mean of the two measurements obtained at 
each V1 step was then calculated and used for analysis. This process was repeated four times in the examination of 
each patch, with the resulting traces averaged to make up experimental records for display and analysis. Figure 2 
illustrates records of observed currents (Fig. 2a), and the resulting activation current-voltage (Fig. 2b) and inac-
tivation curves (Fig. 2c) obtained from the observed peak currents I1 and I2 shown separately for each repeat. 
These demonstrate the consistency of the findings obtained from a patch that was studied that gave stable results 
throughout the duration (Fig. 2(i–iv)) of the experimental protocols.
Figure 1. Experimental loose patch configuration: (a) Pinned muscle preparation under Krebs-Henseleit 
solution with loose patch pipette mounted at 45 degrees to the preparation but bent to permit right-angled 
contact of the pipette tip with the myocyte surface. Pipette connected to suction syringe. (b) Equivalent circuit 
of loose patch clamp electrode on membrane. Pipette clamped at voltage Vpip. Compensation for the voltage 
error arising from currents flowing through the series combination of the pipette resistance (Rpip) and the seal 
resistance (Rseal) was achieved using a bridge circuit in the custom-designed loose patch clamp amplifier. As the 
loose patch technique alters the extracellular potential within the patch relative to resting membrane potential 
(RMP), negative V0 and positive V1 and V2 voltage excursions in Vpip respectively produce hyperpolarising 
and depolarising voltage steps relative to RMP as indicated on the ordinate. (c) Pulse protocol imposing three 
voltage steps over a time course of 80 ms before restoring RMP.  A 50 ms duration, −40 mV, hyperpolarising 
pre-pulse voltage step V0 maximises and standardises the initial proportion of Nav channels in the resting as 
opposed to inactivated state. The subsequent V1 depolarising voltage step of varying amplitudes to membrane 
potentials between RMP − 40 and RMP + 120 mV was used to analyse the voltage dependence of Na+ current 
activation. The final V2 voltage step to a fixed potential RMP + 100 mV permitted assessment of Na+ channel 
inactivation reflected in the presence of Na+ current persistent following the preceding V1 step. (d) Typical 
current trace recorded during a single sweep in the experimental protocol to determine quantitative measures 
of activation and inactivation. The peak currents I1 and I2 obtained during the respective voltage steps V1 and 
V2 measured relative to the current immediately before the corresponding voltage step provided measures of 
Na+ current activation and Na+ current inactivation respectively corresponding to the membrane potential at 
the V1 voltage step. Data from patch 2102st05.dat (sweep 18), V0 = −40, V1 = +45, V2 = +100 mV relative to the 
resting potential respectively.
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Comparisons of Na+ currents obtained before and following 8-CPT challenge. Currents were 
first measured before and following treatment with the Epac activator 8-CPT at a final concentration of 1 μmol/L, 
at which it is highly specific for Epac over PKA35 using the same pipette and muscle preparation. Figure 3(a,b) 
illustrate typical loose patch clamp currents obtained from representative patches before (panel a) and following 
(panel b) pharmacological challenge. Currents are normalised to the area of the pipette tip lumen (µm2) to give 
current densities (pA/µm2). The pretreatment inward Na+ currents showed their typical activation and inactiva-
tion time courses (Fig. 3a). The initial test depolarising V1 steps elicited transient inward currents that initially 
increased with time to a peak value that increased non-linearly with progressive depolarisation reflecting the 
voltage-dependence of Na+ current. They then decayed reflecting channel inactivation whose extent and kinetics 
was similarly determined by the voltage V1. Subsequent superimposition of the V2 test steps upon the varying 
V1 voltage excursions to a constant strongly depolarised level (RMP + 100) mV similarly elicited inward Na+ 
currents with typical activation and inactivation time courses. However, the resulting deflections decreased in 
amplitude the more depolarised the V1 excursion. This is as expected for Na+ channel inactivation that is depend-
ent upon, and becomes more marked with, the preceding voltage level V1. In a significant number of records the 
initial inward currents following V1 and V2 steps were followed by a more gradual development of an outward 
current expected from a delayed K+ current activation. However, challenge by 8-CPT markedly decreased the 
inward Na+ current amplitudes whether with the V1 or V2 voltage steps at all the test voltages explored by the V1 
steps (Fig. 3b).
Activation Na+ current-voltage curves before and following 8-CPT challenge. The reduction in 
Na+ currents could be represented in the plots of voltage-dependence of Na+ current activation following the V1 
voltage step (Fig. 3c) before and (Fig. 3d) during treatment with 8-CPT. The voltage-dependence of Na+ current 
activation following the V1 voltage step during the different pharmacological conditions was then plotted in 
Fig. 3c,d. This was obtained from the average value of I1 determined for each patch studied and plotting the result-
ing Na+ current activation (mean of I1 ± standard error of the mean (SEM)) for each value of voltage excursion 
in the V1 step. The rising phases of the current-voltage (I-V) relationships from each patch obtained before and 
Figure 2. Sets of ionic currents, and activation and inactivation current-voltage relationships obtained from 
sequentially repeated pulse protocols through investigation of the properties of a single patch. Displays of (a) 
currents, (b) activation and (c) inactivation current voltage curves through different stages ((i)-(iv)) of the study 
of the single patch illustrated.
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following pharmacological intervention were then characterised by fits to a Boltzmann function: I1 = I = Imax/[1 + 
exp{(V* − V)/k}]), relating the peak current I at any given voltage excursion V1 through a maximum value of such 
peak current (Imax), the voltage V* at half-maximal current activation, and a steepness factor term k. The collected 
n values were then expressed as means ± SEM and values of the parameters compared (a) before and (b) during 
drug treatment by unpaired 2-tailed t-testing to a P < 0.05 significance level.
The values of Imax, V* and k for the activation I-V curves under each pharmacological condition were expressed 
as means ± SEM (n-value). 8-CPT reduced Na+ current with small changes in its voltage-dependence. Thus, 
although there were similar voltages at half-maximal current, V* (45.61 ± 1.66 mV (n = 6) vs. 45.09 ± 3.35 mV 
(n = 6); t-statistic (t) = 0.13, degrees of freedom (ϕ) = 10, P ≫ 0.05), there were increased values of k, reflecting 
decreased voltage sensitivity of current activation, following addition of 8-CPT (from 3.56 ± 0.62 mV (n = 6) to 
5.75 ± 0.57 mV (n = 6); t = 2.36, ϕ = 10, P < 0.05), and marked reductions in the values of the maximum cur-
rent Imax with 8-CPT challenge (from −99.06 ± 15.19 pA/μm2 (n = 6) to −38.04 ± 4.48 pA/μm2 (n = 6); t = 3.52, 
ϕ = 10, P < 0.01).
Inactivation Na+ current-voltage curves before and following 8-CPT challenge. Concordant 
observations were obtained from analysis of Na+ inactivation. Figure  3e,f plot the corresponding 
voltage-dependence of Na+ current inactivation produced by varying V1 voltage steps prior to the V2 test step to a 
fixed membrane potential (e) before and (f) following treatment with 8-CPT. Peak currents, I2, in response to the 
V2 step are plotted (mean of I2 ± SEM) for each value of voltage excursion in the preceding V1 step. These fell with 
increasing depolarisation produced by the V1 voltage step, reflecting the voltage-dependence of Na+ current inac-
tivation. The dependences of I2 upon V1 for each patch were then characterised by fits to a Boltzmann function: 
I2 = I = Imax(1 − 1/[1 + exp{(V* − V)/k}]), where I is the peak current associated with given voltage excursion V1, 
Imax the maximum peak current, V* the voltage at half-maximal current inactivation, and k the steepness factor 
term. The collected n values were then again expressed as means ± SEM and values of the parameters compared 
during treatment and before drug treatment by unpaired 2-tailed t-testing to a P < 0.05 significance level. The 
values for Imax, V* and k, were expressed as means ± SEM (n-value).
Figure 3. Loose-patch clamp current records obtained before and following 8-CPT challenge. (a,b) Typical families 
of membrane ion currents, dimensioned in pA/μm2, observed (a) before and (b) following 8-CPT challenge 
in response to V1 steps to varying and V2 steps to a fixed membrane potential. Note increase in I1 and decrease 
in I2 with increasingly depolarising V1 steps, and reductions in both I1 and I2 with 8-CPT treatment. (c–f) Plots 
(means ± SEM) of peak inward currents, I1 and I2, in response to (c,d) V1 steps and (e,f) V2 steps respectively 
reflecting voltage dependences of inward current (c,d) activation and (e,f) inactivation (c,e) before and (d,f) 
following 8-CPT challenge. Data from (a,c,e) patch 2702st03.dat (sweeps 1–66), (b,d,f) patch 2702st06 (sweeps 
1–66); V0 = −40, V1 = from −40 to +120, V2 = +100 mV relative to the resting potential for both data sets.
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Analysis of inactivation data demonstrated again that introduction of 8-CPT resulted in marked reduc-
tions in the inward current. There were similar voltages at half-maximal current, V* (30.70 ± 1.23 mV (n = 6) 
vs. 25.78 ± 2.35 mV (n = 9); t = 1.78, ϕ = 13, P ≫ 0.05), but increases in k (from 8.82 ± 0.20 mV (n = 6) to 
10.24 ± 0.28 mV (n = 9); t = 4.13, ϕ = 13, P < 0.01), demonstrating slightly decreased voltage sensitivities of peak 
current inactivation, following addition of 8-CPT. There were also pronounced reductions in the values of the 
maximum current Imax with 8-CPT challenge (from 71.86 ± 9.96 pA/μm2 (n = 6) to 34.61 ± 3.50 pA/μm2 (n = 9); 
t = 4.48, ϕ = 13, P < 0.001).
Na+ current timecourses before and following 8-CPT challenge. 8-CPT did not produce major 
kinetic changes in the observed Na+ currents. This is illustrated by comparing time courses of the inward currents 
following the V1 voltage step before and following 8-CPT challenge. Figure 4a illustrates such currents, dimen-
sioned in nA, obtained by signal averaging currents from the parts of the sweeps imposing V1 steps between 
(RMP + 40) and (RMP + 120) mV from a single patch employing the pulse protocol (a) before and (b) following 
challenge by 8-CPT. Figure 4c shows that traces normalised to their peak values obtained before (solid lines) and 
following (dotted lines) at different V1 excursions were superimposable at least in the initial stages following the 
depolarising steps. This was apart from small differences at deflections of 40 mV which are consistent with the 
shallower voltage dependence of both activation and inactivation observed in the presence of 8CPT.
Control results from challenge with dantrolene in combination with 8-CPT. The above exper-
iments thus demonstrated significant effects on Na+ current magnitudes following challenge by extracellular 
8-CPT, in intact cardiomyocytes whilst minimising intracellular perturbations. In view of its lipophilic nature and 
its intracellular Epac-dependent site of action, reversibility of these actions was tested by challenge using dantro-
lene in combination with 8-CPT. Dantrolene is known to exert, similarly intracellular, actions directly blocking 
RyR-mediated release of SR Ca2+ whether added extracellularly or injected36. The final experiments that followed 
applied dantrolene challenge alone in the absence of 8-CPT, to control for any intrinsic actions of dantrolene on 
Na+ current. This strategy thus tested the reversibility of the intracellular effects of Epac activator on RyR medi-
ated actions on Na+ channel function through matching this with applications of a known RyR antagonist. In 
addition, adopting this control strategy thus additionally directly confirmed a hypothesis attributing the observed 
8-CPT actions on Na+ current to actions on the RyR-Ca2+ release channel.
The subsequent experiments accordingly explored the extent to which the effects outlined above could be 
abrogated by challenge with a combination of 8-CPT (1 µM) and dantrolene (10 µM). Dantrolene is a known 
RyR blocker. It could therefore be used to test for an involvement of RyR-mediated Ca2+ release in the effects 
of Epac activation on Na+ channel function, by exploring whether it would abrogate the effect of 8-CPT. In 
Figure 4. Time courses of currents before and following 8-CPT challenge. Comparison of time course of inward 
currents before and following 8-CPT challenge. (a,b) currents dimensioned in nA, obtained by signal averaging 
currents from sweeps imposing V1 steps between RMP + 40 and RMP + 120 mV in a single patch employing the 
pulse protocol (a) before and (b) following challenge by 8-CPT. (c) Superimposed traces obtained before (solid 
lines) and following (dotted lines) both normalised to their peak values at different levels of depolarisation from 
the RMP. Data from (a) patch 2702st03.dat (sweeps 17–50, 83–116, 149–182 and 215–248), (b) patch 2702st10 
(sweeps 17–50, 83–116, 149–182 and 215–248); V0 = −40, V1 = from +40 to +120, V2 = +100 mV relative to the 
resting potential for both data sets.
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these control experiments, simultaneous administration of 8-CPT and dantrolene resulted in current amplitudes 
similar to those observed before pharmacological challenge, indicating that the effect of 8-CPT in inhibiting 
Na+ current was abolished (Fig. 5a,b). This was reflected in the activation and inactivation I-V curves shown 
in Fig. 5(c,d) and 5(e,f) respectively. Thus, fits of the appropriate Boltzmann expression to the activation data, 
before and following pharmacological challenge demonstrated similar values for Imax (−43.06 ± 6.07 pA/μm2 
(n = 8) vs. −37.60 ± 6.62 pA/μm2 (n = 13); t = 0.54, ϕ = 19, P ≫ 0.05), V* (49.92 ± 1.44 mV (n = 8) vs. 
46.79 ± 0.80 mV (n = 13); t = 1.96, ϕ = 19, P ≫ 0.05), and k (7.30 ± 0.62 mV (n = 8) vs. 6.32 ± 0.36 mV (n = 13); 
t = 1.39, ϕ = 19, P ≫ 0.05). Similar fits of Boltzmann functions to inactivation data gave concordant results for 
which Imax was 38.77 ± 5.47 pA/μm2 (n = 8) and 32.62 ± 6.00 pA/μm2 (n = 13) (t = 0.68, ϕ = 19, P ≫ 0.05); V* 
was 28.50 ± 3.19 mV (n = 8) and 25.57 ± 2.16 mV (n = 13) (t = 0.76, ϕ = 19, P ≫ 0.05); and k was 11.33 ± 0.49 mV 
(n = 8) and 11.31 ± 0.85 mV (n = 13) (t = 0.01, ϕ = 19, P ≫ 0.05). As treatment with dantrolene could reverse the 
effects of 8-CPT on Na+ current amplitudes, activation of RyR is likely involved in this 8-CPT-induced inhibition 
of Na+ currents.
Control results from challenge with dantrolene alone. The above results are consistent with a hypoth-
esis implicating a RyR-dependent Ca2+ release providing a mechanism by which Epac activation by 8-CPT com-
promised Na+ channel function. The final controls accordingly investigated the effect of RyR block by dantrolene 
(10 µM) alone (Fig. 6). Analysis of the resulting experimental traces before (a) and following (b) dantrolene treat-
ment (Fig. 6a,b) demonstrated that dantrolene did not exert any direct effects on Na+ current activation or inac-
tivation. Thus, challenge by dantrolene alone produced results closely similar to findings following combined 
8-CPT and dantrolene challenge. Analysis of activation curves (Fig. 6c,d) gave activation curve values of Imax, V*, 
and k that were unchanged before and following dantrolene challenge. They gave for Imax, −54.54 ± 4.44 pA/μm2 
(n = 7) and −53.60 ± 9.26 pA/μm2 (n = 7) (t = 0.08, ϕ = 12, P ≫ 0.05); V*, 49.43 ± 1.53 mV (n = 7) and 
45.91 ± 1.78 mV (n = 7) (t = 1.39, ϕ = 12, P ≫ 0.05); and k, 5.63 ± 0.54 mV (n = 7) and 5.53 ± 0.61 mV (n = 7) 
(t = 0.12, ϕ = 12, P ≫ 0.05). Similarly, the inactivation data (Fig. 6e,f) gave for Imax, 49.42 ± 4.44 pA/μm2 (n = 7) 
and 41.91 ± 7.24 pA/μm2 (n = 7) (t = 0.99, ϕ = 12, P ≫ 0.05); V*, 30.40 ± 1.72 mV (n = 7) and 26.75 ± 2.20 mV 
(n = 7) (t = 1.46, ϕ = 12, P ≫ 0.05); and k, 10.19 ± 0.66 mV (n = 7) and 9.91 ± 0.53 mV (n = 7) (t = 0.37, ϕ = 12, 
P ≫ 0.05). Therefore, as dantrolene alone was unable to affect Na+ currents, the reversal of 8-CPT action by 
Figure 5. Inclusion of dantrolene abolishes the inhibitory effect of 8-CPT on inward currents. (a,b) 
Membrane ion currents (a) before and (b) following challenge by a combination of 8-CPT and dantrolene 
in response to pulse protocol consisting of V1 and V2 steps showing increased I1 and decreased I2 with 
increasingly depolarising V1 steps that were not affected by the pharmacological challenge. (c–f) Plots of 
peak inward currents, I1 and I2, in response to (c,d) V1 steps and (e,f) V2 steps respectively. These reflect the 
voltage dependences of inward current (c,d) activation and (e,f) inactivation (c,e) before and (d,f) following 
pharmacological challenge. Data from (a,c,e) patch 2102st03.dat (sweeps 1–66), (b,d,f) patch 2102st05 (sweeps 
1–66); V0 = −40, V1 = from −40 to +120, V2 = +100 mV relative to the resting potential for both data sets.
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dantrolene is due to interference of the inhibitory action of 8-CPT and not by the direct actions of dantrolene on 
Na+ currents.
Discussion
The present experiments demonstrate for the first time a downstream modulation of skeletal muscle Nav1.4 func-
tion by the recently characterised Epac signalling system, brought about by its action on RyR1-mediated release of 
intracellularly stored Ca2+. Intense recent interest has been directed at such PKA-independent activation mecha-
nisms in distinct critical cell physiological processes. Yet there have been no studies of their actions on excitable as 
opposed to metabolic function1,2 in skeletal muscle, particularly its RyR1-mediated signalling, or further down-
stream effects on Nav1.4 function. Although such studies on Epac action have been made on cardiac myocytes4–6, 
skeletal muscle activation is distinct in its involving direct charge-coupled as opposed to Ca2+-induced Ca2+ 
release by RyR1 rather than RyR2, driven by surface membrane Cav1.1 as opposed to Cav1.2 activation following 
depolarisation, that does not involve Ca2+ current. Furthermore, these events are initially driven by Nav1.4 rather 
than Nav1.5 opening19. The present experiments demonstrated inhibitory effects on skeletal muscle Nav1.4 acti-
vation by the Epac activator 8-CPT. These were reversed by the RyR-blocker dantrolene. Yet dantrolene challenge 
by itself did not affect Na+ current. The observed effects on Nav1.4 kinetics, and activation and inactivation steady 
state properties were quantifiable in terms of maximum currents, steepness factors and half-maximal voltages.
The experimental procedures used loose patch clamp methods, apposing micropipettes on the surface mem-
branes of intact skeletal myocytes. This formed relatively low resistance, <~2 MΩ, seals37 avoiding membrane or 
cellular disruption thereby leaving intracellular, particularly [Ca2+]i, homeostasis unperturbed. This approach can 
be applied to intact cells in tissue preparations in situ and further permits pipette re-use in successive recording 
protocols38,39. Currents from the same pipette before and after drug treatment could therefore be compared at 
multiple recording sites within the same in situ muscle fibre. In contrast, conventional tight seal patch clamping 
methods often include Ca2+-sequestrating ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
(EGTA) in the pipette solutions that could perturb intracellular Ca2+ homeostasis, often require isolated or cul-
tured cells and enzyme-cleaning of membranes, and involve pipette replacement between successive patches.
The cAMP analogue and Epac agonist 8-CPT3 was applied at concentrations (~1 µM) considered 300-fold pref-
erentially selective for Epac over PKA activated pathways3,40–42. Although 8-CPT also inhibits phosphodiesterase 
Figure 6. Inclusion of dantrolene alone leaves inward currents unchanged. (a,b) Membrane ion currents (a) 
before and (b) following challenge by dantrolene alone in response to pulse protocol consisting of V1 and V2 
steps. Note increased I1 and decreased I2 with increasingly depolarising V1 steps that were not affected by the 
pharmacological challenge. (c–f) Plots of peak inward currents, I1 and I2, in response to (c,d) V1 steps and 
(e,f) V2 steps respectively. These reflect the voltage dependences of inward current (c,d) activation and (e,f) 
inactivation (c,e) before and (d,f) following pharmacological challenge. Data from (a,c,e) patch 2802st02.dat 
(sweeps 1–66), (b,d,f) patch 2802st06 (sweeps 1–66); V0 = −40, V1 = from −40 to +120, V2 = +100 mV relative 
to the resting potential for both data sets.
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isoforms, it only does so at considerably higher concentrations43. Firstly, in common with the previous find-
ings in murine cardiac, atrial and ventricular muscle4, 8-CPT reduced skeletal muscle cell Na+ current ampli-
tudes whether quantified from peak currents, Imax, or measurements from both activation and inactivation 
current-voltage curves. 8-CPT also increased their corresponding steepness factors, k, reflecting decreased Na+ 
channel voltage sensitivities. Secondly, superimposition of scaled membrane currents before and after 8-CPT 
challenge suggested that 8-CPT contrastingly did not affect Na+ current kinetics, other than modest changes 
corresponding to the alteration in Na+ channel voltage sensitivity.
These effects of 8-CPT were abrogated by further addition of dantrolene, in parallel with the previous study in 
cardiac muscle cells4. Dantrolene is a ryanodine receptor (RyR)-sarcoplasmic reticular (SR) Ca2+ channel blocker 
acting through stabilising RyR closed states by enhancing interactions between its N-terminal and the central 
domains particularly under conditions of increased open channel probability44–46. In cardiac muscle, dantrolene 
inhibited RyR2-mediated diastolic Ca2+ release, decreasing frequencies and durations of aberrant Ca2+ sparks in 
cardiomyocytes modeling catecholaminergic polymorphic ventricular tachycardia (CPVT)46 and cardiac fail-
ure models45,47. Its observed action thus implicated mechanisms involving RyR-mediated SR Ca2+ release in the 
observed 8-CPT action on Nav1.5. Furthermore, challenge with dantrolene alone did not affect either Na+ cur-
rent amplitude or values of k. This excludes actions of dantrolene arising from any direct effects on Na+ current. 
Thus, both dantrolene and 8-CPT likely produced their respective effects upon skeletal muscle Nav1.4 through 
a common Ca2+-dependent mechanism. Through these pharmacological procedures, voltages of half-maximal 
activation, V*, for both activation and inactivation were unchanged. Thus, certain regulatory processes that act 
on cardiac Nav1.5 may well also do so in skeletal muscle Nav1.4.
The present findings extend signalling schemes involving Epac-dependent cAMP-triggered activation path-
ways suggested for cardiac muscle to a similar regulation of Na+ channel function in skeletal muscle. First, they 
suggest that skeletal muscle also possesses an Epac signalling pathway capable of influencing ion channel func-
tion. Epac is a guanine nucleotide exchange factor (GEF) for the Ras-like small GTPases Ras-related protein 
(Rap)1 and Rap248. Of the three Epac1, Epac2 and Related to Epac (Repac) isoforms3, Epac2 has been associ-
ated with regulating Ca2+-dependent processes1,2,48, including pancreatic β-cell excitation-secretion coupling49–53 
and activation of spontaneous transient outward currents in vascular smooth myocytes54. In cardiac muscle, 
pro-arrhythmic effects of Epac activators on both spontaneous SR Ca2+ release and diastolic Ca2+ transients6 were 
abolished by genetic ablation particularly of Epac2, as well as of β1 adrenoreceptor, Ca2+/calmodulin-dependent 
protein kinase II-δ (CaMKIIδ), and with RyR2-S2814 phosphorylation12. These effects may involve a novel path-
way in which an activated Epac upregulates Rap1 action in turn stimulating phospholipase C (PLCε) medi-
ated phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis to diacylglycerol (DAG)2,55. DAG triggers a 
protein kinase C (PKC) mediated CaMKII activation in turn promoting a RyR2 phosphorylation associated with 
increased SR Ca2+ release. PLCε also exerts GEF activity that amplifies Rap1 activation initiating further, positive 
feedback, activation of PLCε. Conversely, CaMKII inhibition abolished such Epac-induced alterations in Ca2+ 
homeostasis6.
Secondly, the findings are consistent with the CaMKII activation phosphorylating skeletal muscle RyR1 as it 
does cardiac muscle RyR2. These effects are associated with increased SR Ca2+ release and cytosolic Ca2+. This 
is consistent with their conserved CaMKII phosphorylation sites at potentially regulatory locations in the RyR1/
RyR2 loop connecting their third and fourth repetitive sequences56. Epac activation may also induce inositol 
1,4,5-triphosphate (IP3) receptor (IP3R)-mediated SR Ca2+ release57, likely via IP3 generation from PIP2 by PLCε.
Thirdly, the present findings directly confirm previous in vitro suggestions that the resulting increased [Ca2+]i 
may then inhibit Nav1.4 function in intact skeletal myocytes in situ25,27 in common with its action on cardiac 
Nav1.54,58. Nav1.4 and Nav1.5 isoforms possess similar amino acid sequences consistent with such multiple struc-
tural and functional homologies13. In common with cardiac Nav1.5, Ca2+ could then regulate Nav1.4 through a 
number of possible mechanisms. Thus: (a) an EF-hand motif in the Nav1.5 C-terminus domain was reported to 
directly bind Ca2+ with an affinity typical of Ca2+-sensor proteins14. Such EF-hand-like domains also occur in 
Nav1.4. (b) Ca2+ could bind at EF-hand motifs of CaM that thereby acts as a Ca2+ sensor. The CaM could then 
bind to an isoleucine-glutamine (IQ) domain conserved between Nav1.4 and other Nav isoforms. Thus, CaM 
co-expression with Nav1.4 negatively shifted the steady-state voltage-dependences of Na+ current activation, an 
effect abolished both by expression of a mutant CaM with impaired Ca2+ binding28 and by mutation of the Nav1.4 
IQ domain29. The mutant Nav1.4 remained Ca2+-sensitive, suggesting persistent additional Ca2+-mediated mech-
anisms regulating Nav1.4 gating independent of Nav1.4 IQ domains. Thus: (c) Nav1.4 and Nav1.5 share sites 
phosphorylated by CaMKII action17 to extents dependent on [Ca2+]i. CaMKII activation downstream of the 
Epac2/Rap1/PLCε cascade could also phosphorylate Nav1.4 independently of Ca2+ release. Additionally, CaMKII 
is itself regulated by Ca2+/CaM. (d) Nav1.4 can also be phosphorylated by PKC resulting in reduced Na+ current 
amplitudes in vitro59. Similar activation of PKC by the Epac2/Rap1/PLCε cascade may thus also directly contrib-
ute to the inhibition of Na+ currents. (e) Ca2+ may produce longer-term inhibition of Na+ channel expression: 
gain of function, RyR2-P2328S, mutations appear to downregulate cardiomyocyte Nav1.5 expression60.
Clinical evidence suggests that a [Ca2+]i-dependent inhibition of Nav1.4 could be physiologically important in 
regulating skeletal muscle excitability. Nav1.4 dysfunction has been reported following mutations in its encoding 
SCN4A gene. This may be implicated in skeletal muscle disorders including hyperkalaemic periodic paralysis, 
K+-aggravated myotonia61 and sudden infant death syndrome24. In particular, SCN4A abnormalities resulting 
in Ca2+-dependent Na+ channel dysregulation have been associated with cold- and K+-aggravated myotonias25. 
Thus, a Nav1.4 mutation localised to the EF-hand-like domain was observed in a patient with K+-aggravated 
myotonia62. Patch-clamp analysis of Na+ currents from such mutant channels have showed impaired inactiva-
tion and slowed Na+ current kinetics62. Small defects in Nav1.4 inactivation, which can also occur following 
weakening of Ca2+-dependent inhibition, can also predispose to myotonias61. Finally, the resulting inhibition of 
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myocyte excitability may also contribute to weakness in dystrophic muscle, where resting [Ca2+]i is constitutively 
substantially raised63.
Materials and Methods
This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 
2012 following ethical review and approval by the University of Cambridge Animal Welfare and Ethical Review 
Body (AWERB). Chemical reagents used were purchased from Sigma-Aldrich (Poole, UK) unless otherwise 
stated. Muscle preparations were obtained from C67BL6 wild-type mice housed in a licensed facility at room tem-
perature, given free access to sterile rodent chow and water, and exposed to 12 hour light/dark cycles. Mice were 
killed by cervical dislocation immediately before use by Home Office-licensed personnel, according to Schedule 
1 of the UK Animals (Scientific Procedures) Act (1986). Gastrocnemius and soleus muscles were isolated and 
dissected free of connective tissue. They were bathed in Krebs–Henseleit (KH) solution (mmol/L: NaCl, 130; KCl, 
4.0; HEPES, 1.2; MgCl2, 1.0; CaCl2, 1.8; glucose, 10; and Na-pyruvate, 2.0; pH adjusted to 7.4) during dissection. 
Isolated muscles were transferred intact into the Sylgard-bottomed experimental bath and secured with A1 insect 
pins.
Experiments were performed in the following variants of the basic KH solution into which were introduced 
dimethyl sulfoxide (DMSO) vehicle containing 8-(4-chlorophenylthio)-2′-O-methyladenosine 3′,5′-cyclic 
monophosphate sodium salt (8-CPT) (BIOLOG Life Science Institute, Bremen, Germany) and/or dantrolene 
sodium (LKT Laboratories Inc, St Paul, MN, USA), or neither agent. Solutions thus contained: (1) KH control 
solution, (2) KH + 8-CPT (1 μmol/L) (3) KH + 8-CPT (1 μmol/L) + dantrolene (10 μmol/L) and (4) KH + dant-
rolene (10 μmol/L), with <0.02% DMSO vehicle in all cases. These solutions were first filtered to remove particles 
with a diameter greater than 10 μm using standard filtration paper (Millipore, Bedford, MA, USA). Control of 
the bath temperature was important as Na+ conductance is dependent on temperature64. Bath temperature was 
controlled at 24–26 °C by circulating heated water through a coil in the bath, a temperature range chosen to opti-
mise Na+ currents observed as well as preparation lifespan. The bath solution was replaced with fresh KH solution 
every 30 min to prevent metabolite accumulation around the muscle preparation and obviate evaporation.
A Flaming/Brown micropipette puller (model P-97, Sutter Instrument Co. Novato, CA, USA) was used to 
pull pipettes from borosilicate glass capillaries (catalog no GC150-10: Harvard Apparatus, Cambourne, Cambs, 
UK) for the loose patch clamp studies. The pipettes were visualised under a microscope at 250x magnification 
and the tips scored using a diamond knife to form a small groove. A force was then applied distal to the groove. 
This caused the pipette tip to break off perpendicular to the long axis of the pipette. The squarely-broken tips were 
visualised at 400x magnification and fire-polished with an electrically-heated nichrome filament to smooth the 
edges of the tip. The internal diameter of the pipettes was measured at 400x magnification. Only pipettes with tips 
which had a very smooth edge perpendicular to the long axis of the pipette and internal diameters of 25–30 µm 
after polishing were selected. The pipette was then bent about 1 mm from its tip to an angle of ~45° relative to its 
long axis, to allow the pipette tip to contact the membrane of the muscle preparation at 90° when mounted on the 
recording amplifier head stage, as depicted in Fig. 1a. The pipettes were mounted on to the pipette holder in the 
experimental setup. The distal half of the micropipette was filled with the KH solution from the bath, with the 
help of suction provided by a syringe via an air-filled connection with the pipette holder. The bath was actively 
grounded at reference potential to complete the circuit. Ag/AgCl electrodes were used to provide a reversible 
electrical connection between the bath solution and the physical electronic circuit.
For loose patch clamp studies, the pipette tip was lowered perpendicular to the membrane of the muscle 
preparation. A gentle suction was applied to form a seal around the patch of membrane under the pipette. The 
technique thus does not involve impalement of the cell membrane in an accordingly intact muscle fibre (Fig. 1b). 
The current flowing across this patch of membrane drawn into the pipette tip could thus be measured by the 
recording electrode in the pipette, relative to the actively-grounded reference potential of the bath. The potential 
across the membrane within the patch then corresponds to the cell resting membrane potential (RMP) prior to 
application of the pulse protocols. The pulse protocols then clamped the voltage of the fluid within the pipette 
through their sequence of command potentials. This in turn accomplished the required changes in potentials 
across the membrane within the patch. As the voltages are thus applied from the extracellular rather than the 
intracellular space, a negative voltage step represents hyperpolarisation and a positive voltage step represents 
depolarisation of the patch relative to RMP. Membrane potentials in this paper are thus described relative to the 
RMP, and imposed voltage changes described as changes in intrapipette potential.
The equivalent circuit of a typical patch is shown in Fig. 1b. The relatively low seal resistance, of typically 
<2 MΩ in this loose as opposed to conventional gigaseal patch clamp technique, resulted in a substantial leak 
current. This ohmic leakage, together with the current flowing through the pipette capacitance, was largely sub-
tracted by the custom-built electronic circuitry of the loose patch clamp amplifier, which also corrected for the 
effects on the clamped membrane potential of pipette series resistance. The remaining leakage currents were then 
corrected for using a P/4 leak protocol. During this protocol which was applied following the test steps them-
selves, four voltage steps of a quarter of the amplitude and of opposite sign were applied to the membrane patch. 
These were of a sign and/or amplitude which would not activate the voltage-gated conductances, thus represent-
ing the leak currents only. The responses were measured, summed and subtracted from the currents obtained 
from the larger original voltage steps, thus correcting for any residual linear leakage currents not already removed 
by the voltage clamp circuit.
An IBM-compatible computer was used to deliver voltage clamp steps relative to the RMP. To detect the pres-
ence of ion channels in the membrane patch being studied, depolarising pulses of (RMP + 100) mV lasting 15 ms 
were first applied. Only patches which produced clearly resolved inward currents with kinetics characteristic of 
Nav channels were selected. A double pulse protocol (Fig. 1c) was then used to assess Na+ current activation and 
inactivation properties in a single sweep. The voltage-dependent activation and inactivation properties of Na+ 
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currents could thus be investigated before and following introduction of the various drugs. More detail on the 
pulse protocol is discussed in the Results section. Data was sampled at a 50 kHz digital sampling rate and filtered 
with a DC-10 kHz bandwidth, using a 10 kHz Bessel low pass filter. The currents obtained from the double pulse 
protocol were normalised to the pipette tip cross-sectional area to give current densities, using the formula:
=
×
π ×
µ
µ
current density (pA/ m ) current measured (nA) 1000
[pipette radius ( m)]
2
2
Analysis of each pharmacological condition compared data collected during the treatment with the drug(s) 
with data collected before treatment, employing Student’s unpaired 2-tailed t-test to a significance level of p-value 
(P) < 0.05. Pre-treatment data was kept in three separate groups depending on the subsequent pharmacological 
treatment due to the large variation in Na+ currents observed between muscle preparations. As the same muscle 
preparations were used to collect data before and during treatment with the drug(s), comparisons before and dur-
ing drug treatment could be made. Curve fitting procedures applied to activation and inactivation current voltage 
curves were carried out by the open source fitting algorithms QtiPlot (Version 0.9.8.9 svn 2288).
ethical approval. This research has been regulated under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review and approval by the University of Cambridge Animal 
Welfare and Ethical Review Body (AWERB). All procedures were completed by Home Office-licensed personnel 
and fell within the scope of Schedule 1 of the UK Animals (Scientific Procedures) Act (1986).
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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